ARVN vs. VRNA, SNDX, CVAC, MORF, KDNY, PLRX, RNA, NUVL, RCKT, and IRWD
Should you be buying Arvinas stock or one of its competitors? The main competitors of Arvinas include Verona Pharma (VRNA), Syndax Pharmaceuticals (SNDX), CureVac (CVAC), Morphic (MORF), Chinook Therapeutics (KDNY), Pliant Therapeutics (PLRX), Avidity Biosciences (RNA), Nuvalent (NUVL), Rocket Pharmaceuticals (RCKT), and Ironwood Pharmaceuticals (IRWD). These companies are all part of the "pharmaceutical preparations" industry.
Arvinas vs.
Arvinas (NASDAQ:ARVN) and Verona Pharma (NASDAQ:VRNA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.
Verona Pharma has lower revenue, but higher earnings than Arvinas. Verona Pharma is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.
Arvinas currently has a consensus target price of $68.75, indicating a potential upside of 159.92%. Verona Pharma has a consensus target price of $29.33, indicating a potential upside of 42.19%. Given Arvinas' higher possible upside, equities analysts clearly believe Arvinas is more favorable than Verona Pharma.
92.0% of Arvinas shares are held by institutional investors. 2.8% of Arvinas shares are held by insiders. Comparatively, 3.9% of Verona Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Arvinas has a beta of 1.78, meaning that its share price is 78% more volatile than the S&P 500. Comparatively, Verona Pharma has a beta of 0.13, meaning that its share price is 87% less volatile than the S&P 500.
In the previous week, Arvinas had 2 more articles in the media than Verona Pharma. MarketBeat recorded 6 mentions for Arvinas and 4 mentions for Verona Pharma. Verona Pharma's average media sentiment score of 0.36 beat Arvinas' score of 0.17 indicating that Verona Pharma is being referred to more favorably in the news media.
Verona Pharma received 152 more outperform votes than Arvinas when rated by MarketBeat users. Likewise, 79.68% of users gave Verona Pharma an outperform vote while only 63.48% of users gave Arvinas an outperform vote.
Verona Pharma has a net margin of 0.00% compared to Arvinas' net margin of -228.19%. Verona Pharma's return on equity of -38.97% beat Arvinas' return on equity.
Summary
Verona Pharma beats Arvinas on 10 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ARVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
